Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

NCT02531126 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02531126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02531126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
December 2, 2015
Completion date
December 19, 2024
Enrollment
877 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis